Carbylan Therapeutics, which is developing a novel, injectable treatment for osteoarthritis pain in the knee, raised $65 million in an upsized IPO by offering 13 million shares (all primary) at $5. Carbylan originally planned to raise $75 million at a $211 million market cap in January, but postponed its IPO before revising its terms on Monday, with plans to offer 12 million shares at $5. The company also added insider buying representing 2.7 million shares, or 21% of the deal size.
At its $5 offer price, Carbylan commands a fully diluted market cap of $125 million and has $65 million in cash on its balance sheet. Carbylan Therapeutics will list on the NASDAQ under the symbol CBYL. Leerink Partners acted as the lead manager on the deal.
Osteoarthritis pain biotech Carbylan Therapeutics prices upsized IPO at $5
April 8, 2015

